Compare MEDP & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MEDP | RNR |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | United States | Bermuda |
| Employees | N/A | 1040 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 12.8B |
| IPO Year | 2016 | N/A |
| Metric | MEDP | RNR |
|---|---|---|
| Price | $449.54 | $280.59 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 12 | 14 |
| Target Price | ★ $473.17 | $322.31 |
| AVG Volume (30 Days) | 309.6K | ★ 362.5K |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.53% |
| EPS Growth | ★ 20.98 | N/A |
| EPS | ★ 4.28 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.19 | N/A |
| Revenue Next Year | $7.75 | $3.19 |
| P/E Ratio | $104.64 | ★ $5.42 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $291.28 | $231.17 |
| 52 Week High | $628.92 | $318.20 |
| Indicator | MEDP | RNR |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 30.82 |
| Support Level | $447.80 | $266.08 |
| Resistance Level | $477.04 | $285.26 |
| Average True Range (ATR) | 14.05 | 7.20 |
| MACD | 5.18 | -1.50 |
| Stochastic Oscillator | 90.75 | 5.31 |
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.